Last reviewed · How we verify
Dual antithrombotc therapy-1
Dual antiplatelet therapy combines two agents that work through different pathways to inhibit platelet aggregation and reduce thrombotic events.
Dual antiplatelet therapy combines two agents that work through different pathways to inhibit platelet aggregation and reduce thrombotic events. Used for Acute coronary syndrome, Percutaneous coronary intervention with stent placement, Secondary prevention of myocardial infarction and stroke.
At a glance
| Generic name | Dual antithrombotc therapy-1 |
|---|---|
| Also known as | DAT-1 |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Drug class | Antiplatelet agent combination |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
This combination therapy typically pairs an antiplatelet agent (such as aspirin or a P2Y12 inhibitor) with another antiplatelet drug to provide synergistic inhibition of platelet function through distinct mechanisms. The dual approach reduces the risk of stent thrombosis, myocardial infarction, and stroke by preventing platelet-mediated clot formation more effectively than monotherapy.
Approved indications
- Acute coronary syndrome
- Percutaneous coronary intervention with stent placement
- Secondary prevention of myocardial infarction and stroke
Common side effects
- Bleeding
- Gastrointestinal hemorrhage
- Dyspepsia
- Bruising
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: